|
MGMT and clinical trials (further
additions will be welcomed)
Yung WK, Albright RE, Olson J, Fredericks R, Fink K,
Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H,
Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N,
Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs.
procarbazine in patients with glioblastoma multiforme at first relapse.
Br J Cancer 83:588–593
Middleton MR,
Lee SM, Arance A, Wood M, Thatcher N, Margison GP (2000)
O6-methylguanine formation, repair protein depletion and clinical
outcome with a 4 hr schedule of temozolomide in the treatment of
advanced melanoma: results of a phase II study. Int J Cancer 88:469–473
Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor
I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE,
Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S,
Garcia-Turner AM, Herndon JE 2nd, Bigner DD, Dolan ME (2000) Phase I
trial of carmustine plus O6-benzylguanine for patients with recurrent or
progressive malignant glioma. J Clin Oncol 18:3522–3528
Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH,
Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC,
McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE II,
Bigner DD, Friedman HS (2002) Phase II trial of carmustine plus
O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or
progressive malignant glioma. J Clin Oncol 20:2277–2283
Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM,
Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE,
Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey
JE, Maxwell J, Tourt-Uhlig S, Herndon JE II, Bigner DD, Friedman HS
(2005) Phase I trial of temozolomide plus O6-benzylguanine for patients
with recurrent or progressive malignant glioma. J Clin Oncol
23:7178–7187
Ranson, M., Middleton,
M.R., Bridgewater, J., Lee, S.M., Dawson, M., Jowle, D., Halbert, G.,
Waller, S., McGrath, H., Gumbrell, L., et al. (2006). Lomeguatrib, a
potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety,
pharmacodynamic, and pharmacokinetic trial and evaluation in combination
with temozolomide in patients with advanced solid tumors. Clin Cancer
Res 12, 1577-1584.
Ryan, C.W.,
Dolan, M.E., Brockstein, B.B., McLendon, R., Delaney, S.M., Samuels, B.L.,
Agamah, E.S., and Vokes, E.E. (2006). A phase II trial of
O6-benzylguanine and carmustine in patients with advanced soft tissue
sarcoma. Cancer Chemother Pharmacol 58, 634-639.
Gajewski, T.F., Sosman, J., Gerson, S.L., Liu, L., Dolan, E., Lin, S.,
and Vokes, E.E. (2005). Phase II trial of the O6-alkylguanine DNA
alkyltransferase inhibitor O6-benzylguanine and
1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer
Res 11, 7861-7865.
Fontes,
A.M., Davis, B.M., Encell, L.P., Lingas, K., Covas, D.T., Zago, M.A.,
Loeb, L.A., Pegg, A.E., and Gerson, S.L. (2006).
Differential competitive resistance to methylating versus
chloroethylating agents among five O6-alkylguanine DNA alkyltransferases
in human hematopoietic cells. Mol Cancer Ther 5, 121-128.
|